Hamza Celik

New in NatureGenetics! 🧠
We illustrated the cover submission for this paper on epigenetic editing of memory expression, a beautiful take on molecular memory. Congrats to all authors!
@graeffjohannes.bsky.social
@dmcoda.bsky.social

We are hiring 😀

Postdoctoral position – Stem cells, Cancer, and Aging

We study cell fate decision and lineage specification in hematopoietic stem and multipotent progenitor populations to modulate lineage output for therapeutic purpose in diseases and aging contexts.

Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications - Current Hematologic Malignancy Reports Purpose of Review More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MPN), advances in the understanding of CALR-mutant MPN continu...

Delighted to share our #hematology review article on mutant calreticulin in #MPN
Congrats to co-authors Drs. Mifra Faiz, Merle Riedemann & Jonas Jutzi. We hope it’s a useful resource, link below! @stanforddeptmed.bsky.social
link.springer.com/article/10.1...

🎉 Happy New Year from #DrawImpacts Studio! 🎨
We’re thrilled to kick off 2025 with exciting news: our first cover of the year has been selected for #CellStemCell 's first issue of 2025!! To another year of impactful collaborations, science, and creativity—we can’t wait to see what this year brings! 🌟

A nice review in @bloodjournal.bsky.social of all things menin in AML!

ashpublications.org/blood/articl...

Will definitely work with Emma👇

Illustration Covers — DrawImpacts I highly recommend DrawImpacts. The illustrations provided by Emma were outstanding. I have been very impressed by the very quick turn-around, efficiency and high-quality of the illustrations. She is ...

@drawimpacts.bsky.social might be able to help: www.drawimpacts.com/logo-design

The dynamics of hematopoiesis over the human lifespan - Nature Methods This Resource presents an atlas classifying the age-related changes in human hematopoietic stem and progenitor cells from gestation through aging.

Hey all you #ASH24 people.
You need to look at this new paper in @naturemethods.bsky.social by Heme extraordinaires Grant Rowe and the Bluesky-less #HojunLi.

A paper that looks at Blood & Time from @bloodandtime.bsky.social himself!

#scRNAseq
#bioinformatics
🧬 💻

www.nature.com/articles/s41...

What does the circulating proteome teach us about common heart diseases?

Thrilled to share our analysis identifying new biomarkers, drug targets, and prediction models for these conditions.

Mentored (supremely) by @mchonig.bsky.social and @pnatarajanmd.bsky.social nature.com/articles/s44... (1/x)

Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN Key PointsWe describe the characterization of INCA033989, a monoclonal antibody that potently and selectively targets mutCALR-positive MPN cells.Data show

Congrats to all involved in this study of a monoclonal antibody targeting mutant CALR in #MPN, first presented at #ASH23, this mAb is now in a phase 1 multicenter clinical trial, open at Stanford #Hematology @stanforddeptmed.bsky.social @bloodjournal.bsky.social
ashpublications.org/blood/articl...

Fast-track activation accelerates clinical trial for blood cancer treatment A clinical trial investigating a promising blood cancer therapy treated its first patient in August 2024 after receiving fast-track activation from the Stanford Cancer Institute in March 2024.

Congrats to Dr. Jason Gotlib on opening a JAK2V617F selective inhibitor trial at Stanford #Hematology in record time! This is a new class of #JAK2 inhibitor, phase 1 trial for patients with myelofibrosis & JAK2V617F is open & recruiting! @stanforddeptmed.bsky.social
med.stanford.edu/cancer/about...

Excited for #ASH24 & thrilled that *3* brilliant folks from the team have oral presentations, travel awards and 2/3 nominated for **best of ASH**!! @imm.ox.ac.uk @ox.ac.uk @cancerresearchuk.org @ludwigcancer.bsky.social

very cool paper by @mpndoc.bsky.social et al looking at RSK1 as a therapeutic target in FLT3-ITD AML!

www.nature.com/articles/s41...

Look who's here
@pnas.org ✔️
@science.org ✔️
@naturecellbiology.bsky.social ✔️
@natrevgenet.bsky.social ✔️
@naturebiotech.bsky.social ✔️
@naturemicrobiol.bsky.social ✔️
@naturechemistry.bsky.social ✔️
@genesdev.bsky.social ✔️
@cellchembiol.bsky.social ✔️
@genomeresearch.bsky.social ✔️
@jcellbiol.bsky.social ✔️

The diverse roles of neutrophils from protection to pathogenesis Nature Immunology - In this Review, Herro and Grimes summarize the most recent key findings surrounding protective versus pathogenic functions of neutrophils, elaborating on phenotype-specific...

Are neutrophils "good" or "bad"?
Rana Herro reviews the current literature here: rdcu.be/d0Rt7

Hi, I’m Emma Vidal, founder of #DrawImpacts, a creative agency specializing in striking cover art for leading journals, scientific figures, logos, slides & web design tailored to the scientific community

We’re new here and excited to connect! Let’s make an impact together!✨🚀 #SciArt
drawimpacts.com

Download our database of 492 (!) funding opportunities for EARLY-CAREER FACULTY AND RESEARCHERS.

For each entry, we provide link to funder, description, amount, deadline, and eligibility criteria (e.g. citizenship).

Download freely here: research.jhu.edu/rdt/funding-...

Genotype-immunophenotype relationships in NPM1-mutant AML clonal evolution uncovered by single cell multiomic analysis Acute myeloid leukemia (AML) is a multi-clonal disease, existing as a milieu of clones with unique but related genotypes as initiating clones acquire subsequent mutations. However, bulk sequencing can...

First manuscript from Linde Miles Lab at CCHMC looking at clonal evolution in NPM1-mut AML at single cell resolution. Check out the pre-print here: www.biorxiv.org/content/10.1...

Finally- the starter pack we have all been waiting for is here … Hematopoiesis 🎉❤️🩸🦴

So excited to have reached a critical mass of this community on here. 🙌🏻
Let me know if you want to be added!!

go.bsky.app/KWdX5w7

FDA approves revumenib for relapsed or refractory acute leukemia On November 15, 2024, the FDA approved revumenib (Revuforj, Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a KMT2A translocation.

It’s always a great start to the day to learn we have one more drug to offer patients with r/r leukemia! 🎗️🩸💊 www.fda.gov/drugs/resour...